Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie’s immunosuppressant portfolio helps it to produce steady revenue and profits.
Source: https://www.fool.com/investing/2026/01/19/best-healthcare-st…
